Education
About Us
Working with TipRanks
Follow Us
Thermo Fisher Scientific (TMO)
NYSE:TMO
TMO Stock Chart & Stats
$508.58
$0.83(0.15%)
At close: 4:00 PM EST
$508.58
$0.83(0.15%)
Day’s Range― - ―
52-Week Range$385.46 - $643.99
Previous CloseN/A
Volume471.20K
Average Volume (3M)2.37M
Market Cap
$188.93B
Enterprise Value$221.88B
Total Cash (Recent Filing)$10.11B
Total Debt (Recent Filing)$40.85B
Price to Earnings (P/E)29.4
Beta0.69
Next Earnings
Apr 29, 2026EPS Estimate
5.27Next Dividend Ex-DateN/A
Dividend Yield0.3%
Share Statistics
EPS (TTM)6.57
Shares Outstanding371,484,250
10 Day Avg. Volume1,757,255
30 Day Avg. Volume2,372,065
Financial Highlights & Ratios
PEG Ratio4.51
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue4.98
Enterprise Value/Gross Profit12.62
Enterprise Value/Ebitda19.33
Forecast
1Y Price Target
$677.73Price Target Upside33.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)24.58
Revenue Forecast (FY)$46.87B
Bulls Say, Bears Say
Bulls Say
Bioproduction And CDMO DemandAnalyst notes that constrained sterile fill-finish capacity and rising demand from biotech firms are boosting the company's CDMO order flow, supporting revenue growth potential in bioproduction services.
Integrated Accelerator CapabilityAnalyst highlights that combining CDMO and clinical CRO capabilities into an integrated Accelerator can shorten drug development timelines and generate larger, faster orders from biopharma customers.
Semiconductor Onshoring OpportunityAnalyst expects the company to benefit from accelerating semiconductor onshoring in the U.S., creating new demand for its analytical instruments and production tools.
Bears Say
CFO Change And Guidance UncertaintyAnalyst highlights that a change in the chief financial officer adds uncertainty to the guidance process and could create short-term investor unease about financial forecasting.
Conservative Near-term GuidanceAnalyst warns that lowered near-term growth guidance signals a cautious end-market outlook that may limit upside unless demand recovery accelerates.
Margin PressureAnalyst points out that adjusted operating and gross margins came in below expectations, indicating profit margin pressure that could weigh on earnings if cost efficiency does not improve.
Thermo Fisher News
TMO FAQ
What was Thermo Fisher Scientific’s price range in the past 12 months?
Thermo Fisher Scientific lowest stock price was $385.46 and its highest was $643.99 in the past 12 months.
What is Thermo Fisher Scientific’s market cap?
Thermo Fisher Scientific’s market cap is $188.93B.
When is Thermo Fisher Scientific’s upcoming earnings report date?
Thermo Fisher Scientific’s upcoming earnings report date is Apr 29, 2026 which is in 56 days.
How were Thermo Fisher Scientific’s earnings last quarter?
Thermo Fisher Scientific released its earnings results on Jan 29, 2026. The company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.449 by $0.121.
Is Thermo Fisher Scientific overvalued?
According to Wall Street analysts Thermo Fisher Scientific’s price is currently Undervalued.
Does Thermo Fisher Scientific pay dividends?
Thermo Fisher Scientific pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 0.3%. See more information on Thermo Fisher Scientific dividends here
What is Thermo Fisher Scientific’s EPS estimate?
Thermo Fisher Scientific’s EPS estimate is 5.27.
How many shares outstanding does Thermo Fisher Scientific have?
Thermo Fisher Scientific has 371,484,250 shares outstanding.
What happened to Thermo Fisher Scientific’s price movement after its last earnings report?
Thermo Fisher Scientific reported an EPS of $6.57 in its last earnings report, beating expectations of $6.449. Following the earnings report the stock price went down -2.608%.
Which hedge fund is a major shareholder of Thermo Fisher Scientific?
Currently, no hedge funds are holding shares in TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$677.73 (33.26% Upside)
$677.73 (33.26% Upside)
Blogger Sentiment
Bullish
TMO Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 677.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $48.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.51%
12-Months-Change
Fundamentals
Return on Equity
13.02%
Trailing 12-Months
Asset Growth
13.38%
Trailing 12-Months
Company Description
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
TMO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: solid top-line growth, strong adjusted EPS growth, robust cash generation, aggressive strategic M&A and product innovation, and constructive 2026 guidance (3%–4% organic growth and 6%–8% EPS growth). Headwinds from tariffs, foreign exchange volatility, China and academic/government softness, margin pressure in Analytical Instruments, and elevated leverage represent notable near-term risks but appear manageable given the company’s PPI-driven productivity, capital deployment discipline, and pipeline of innovations and strategic deals.View all TMO earnings summariesTMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics
TMO Stock 12 Month Forecast
Average Price Target
$677.73
▲(33.26% Upside)
Technical Analysis
Ownership Overview
0.13% Insiders
24.18% Mutual Funds
9.81% Other Institutional Investors
46.45% Public Companies and Individual Investors